Pedro C. Barata MDAssociate Professor of Medicine, Department of Hematology Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH
Dr. Pedro Barata is Board Certified in Internal Medicine and a Medical Oncologist with a focus in genitourinary tumors and clinical trials. He earned his medical degree from the New University of Lisbon in 2009 and completed his medical oncology training in 2016. After completion of his fellowship, he was invited to join the genitourinary group at Taussig Cancer Center, where he worked as a clinical fellow in genitourinary malignancies. Dr. Barata moved to Tulane University to continue his clinical and research work in the GU field and to help expand the genitourinary program offered at Tulane Cancer Center, with a focus on clinical trials. Dr. Barata is currently an Associate Professor of Medicine in the Department of Hematology Oncology at the University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center in Cleveland, Ohio.
Dr. Barata has authored or co-authored dozens of publications in high-quality and pubmed-indexed journals, such as Cancer, Annals of Oncology, and CA: Cancer journal Clinicians. In addition, he has presented multiple abstracts at important national and international meetings and has won multiple prestigious awards, including the Tulane Career Development Award, Clinical Sciences (2021), the Scholar-in-Training Award, AACR-NCI-EORTC Triple Meeting (2017) and the Annual Accelerating Anticancer Agent Development and Validation (AAADV) Program Scholarship (2018).
He serves as a reviewer for prestigious peer-reviewed journals, such as JAMA Oncology, Cancer, Lancet Oncology, ASCO and Journal of Global Oncology and is the Prostate Section Editor of the Oncologist journal and a member of the Editorial Board of the Translation Oncology and Clinical Genitourinary Cancer journals.
Recent Contributions to PracticeUpdate:
- 68-Year-Old Man With mCRPC Who Progressed Post Docetaxel and Abiraterone Acetate
- Integrating PSA Kinetics Into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy
- 59-Year-Old Man With mCRPC Presenting for Second Opinion
- Metastatic CRPC With TP53 and PTEN Mutations
- De Novo Metastatic Castration Sensitive Prostate Cancer in a 73-Year-Old Black Patient
- A 67-Year-Old Man With TP53 Mutation, AR Amplification, and AR-V7 Positive Metastatic Prostate Cancer
- 75 Year Old Man With Non-Metastatic Castration Resistant Prostate Cancer
- Patient With mCRPC With BRCA1+ and High Tumor Mutational Burden
- Adenocarcinoma of Prostate Gleason 5+5
- Systemic Treatment for Patient With Progressing mCRPC